Chinese embodied AI and robotics startup TARS has completed a Pre-A financing round worth $455 million, according to the company and several domestic media reports, marking what has been described as the largest disclosed single-round fundraising and the biggest Pre-A deal yet seen in China’s embodied intelligence sector. The announcement was made on April 16 and follows a previously reported angel round in the second quarter of 2025 that also set a sector record. Together, the two financings suggest that TARS has quickly become one of the best-capitalized startups in a market attracting growing attention from both venture investors and industrial backers.
Financing Details
The company said the latest round was oversubscribed, underscoring strong investor demand for startups building embodied AI systems, which aim to combine large-scale models with robots capable of operating in real-world environments. Chinese media reports said the fundraising exceeded RMB 3 billion in equivalent terms, reinforcing the scale of the transaction in both dollar and local currency terms. TARS positioned the round as another milestone in a financing history that has already stood out in a crowded robotics market, following its earlier angel financing of about $242 million.
Investor Lineup
The syndicate behind the deal reflects a rare mix of financial, strategic, industrial and state-backed capital, highlighting how broad the support base for the company has become. According to the materials provided, Hillhouse Venture Capital and Sequoia China were among the lead investors on the financial side, while Meituan’s strategic investment arm also increased its commitment and continued as a co-lead investor in the round. Additional participants named in the company statement and media coverage included Meituan Long-Z, CICC Capital, Qiming Venture Partners, Linear Capital, BlueRun Ventures, Xianghe Capital, Hongtai Fund, TCL’s investment arm and several government-linked funds from Beijing and Shanghai.
Valuation Outlook
TARS did not publicly disclose an exact valuation in its announcement, but it said its valuation now ranks among the highest in the sector’s top tier. A report from Caijing said the company’s valuation in the current round was about RMB 15 billion, and that its next financing plan has already been outlined at a valuation above RMB 20 billion. That gap between the company’s official wording and media estimates leaves some room for interpretation, but both accounts point to a rapidly rising market value.
Industry Backdrop
The financing arrives at a time when embodied AI has become one of the most closely watched themes in China’s technology investment landscape, with investors increasingly focused on whether robotics startups can convert technical progress into scalable business results. One of the reports noted that capital markets are placing greater emphasis on industrial deployment and commercialization rather than pure concept-driven enthusiasm. Even so, mass production, large-scale delivery and sustainable customer adoption remain difficult hurdles for the wider industry, meaning capital alone will not guarantee leadership.
Strategy and Use of Funds
TARS said the new funding will be used to continue developing its proprietary embodied AI foundation model and to recruit top global talent, two priorities that signal a long-term push to strengthen both software and research capabilities. The company also appears to be emphasizing commercial application across multiple scenarios, a focus reinforced by the participation of industrial investors that could help open deployment channels. That combination of model development, hiring and ecosystem partnerships suggests TARS is trying to build not only technical differentiation, but also a practical route to market.
The new raise cements TARS as one of the most prominent names in China’s embodied AI field, both in terms of capital raised and the stature of its backers. It also highlights how quickly investment appetite can concentrate around a small number of perceived leaders when a technology category begins to move from experimentation toward commercialization. Whether TARS can justify its record-breaking financing will depend less on fundraising momentum from here and more on its ability to turn research ambition into products that can be manufactured, deployed and scaled.